Peritoneal Mesotheliomas Clinical Trial
Official title:
Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.
Observation of primary outcome:
- Overall Survival
- Disease-free survival
Influencing factors that will be observe:
- Sex
- Blood loss
- Time of surgery
- Number of resection and anastomosis
- Peritoneal Index (PI score)
- Cytoreductibility (CCR score)
;
Observational Model: Case-Crossover, Time Perspective: Retrospective